Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
National survey finds HBV rate is four times higher than that of the overall U.S. population.
Investigators analyzed the degree to which various factors predicted ischemic and hemorrhagic strokes in this population.
Researchers analyzed outcomes among infants with hepatitis B who did and did not receive antiviral treatment before age 1.
A new study appears to resolve controversy over hep C treatment’s association with mortality risk.
The drug can quickly reverse an opioid overdose and prevent death.
The presence of less studied HCV genotypes may compromise cure rates.
The first national study of opioid use disorder recovery found that staying off such drugs often requires great effort and various services.
Researchers have identified biomarkers that can identify NAFLD and rule out advanced fibrosis.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Researchers compared health outcomes among people with HIV, including those with and without hepatitis C.
Large European study finds that more than 1 in 10 people with HIV acquire HCV again.
Australia has led the world in an aggressive push to provide its citizens with low-cost treatment for the virus.
The U.S. Preventive Services Task Force gave the recommendation an A rating, meaning screening must be covered with no cost sharing.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
An analysis conducted in Taiwan analyzed health outcomes over more than a decade.
An NIH-sponsored peer-recruitment study is part of a larger push to figure out how to drive up the viral suppression rate in the U.S.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.